An outpatient clinical trial on unresponsive deep-bacterial canine pyoderma (UDCP), without a control group, is presented.The chosen treatment was implemented with a new crystal-solvate of enrofloxacin (enrofloxacin HCl-2H2O or enro-C), in a dual scheme, i.e., 10 mg/kg/day PO, plus its topical administration, prepared as 0.
5% in an alginate gel, thrice per day.Fifty-five cases that were unsuccessfully treated previously with another antibacterial drug, were selected and then classified as severe or very severe, according to a clinical score tailored for this trial.Aerobic bacteriological cultures of skin lesions and antibacterial sensitivity tests, were performed.Hematological status, liver, and kidney functions Queen Slat Headboard were determined before and after treatment.
A complete success was obtained in 32 severe and 23 very severe, cases.The main bacterial isolates were: Staphylococcus intermedius (19/99), Staphylococcus pseudintermedius (16/99), Staphylococcus epidermidis (15/99), Staphylococcus pyogenes (14/99), Staphylococcus saprophyticus, Streptococcus sp., and others including Pseudomonas aeruginosa (6/99).The average duration of treatment Cyclist Accessories - Triathlon - Accessories was 8.
03 days ± 2.1 SD and 12.0 ± 2.4 days, for dogs with severe or very severe UDCP, respectively.
The adverse effects caused by enro-C were inconsequential and the hematological tests showed no deviations from normality.The use of enro-C administered dually to treat UDCP, is considered safe and highly effective.